Payment overview · 2025
General Payments
$923.81
67 reported records · 16 companies
Healthcare provider profile · identity verified
Jason Thomas Bradley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · LUBBOCK, TX · NPI 1073677977
Verified facts
What the public records show
CMS Open Payments records show Jason Thomas Bradley, M.D. received $923.81 in general payments during 2025 across 67 reported records.
Amgen Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1391 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1391 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.33 | 21.8% | 33 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $144.21 | 15.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $90.32 | 9.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.26 | 9.6% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$81.97 | 8.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.63 | 6.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.24 | 5.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.90 | 4.0% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $28.65 | 3.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $28.47 | 3.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.96 | 3.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.76 | 2.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $20.81 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.95 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.46 | 1.6% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $7.89 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $923.81 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $201.33 | 33 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $105.62 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $90.32 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.81 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $60.66 | 3 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.24 | 3 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $38.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.96 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $7.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1391 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1391 | 342 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1391 | 342 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 2023 | 653 |
| Metoprolol Succinate | Metoprolol Succinate | 1959 | 583 |
| Eliquis | Apixaban | 1391 | 342 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1160 | 342 |
| Losartan Potassium | Losartan Potassium | 1064 | 323 |
| Amlodipine Besylate | Amlodipine Besylate | 883 | 291 |
| Furosemide | Furosemide | 861 | 314 |
| Hydrochlorothiazide | Hydrochlorothiazide | 859 | 270 |
| Lisinopril | Lisinopril | 853 | 270 |
| Potassium Chloride | Potassium Chloride | 806 | 289 |
| Carvedilol | Carvedilol | 684 | 208 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 622 | 198 |
| Metoprolol Tartrate | Metoprolol Tartrate | 602 | 174 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 511 | 150 |
| Ezetimibe | Ezetimibe | 507 | 150 |
| Repatha Sureclick | Evolocumab | 408 | 65 |
| Xarelto | Rivaroxaban | 391 | 102 |
| Pravastatin Sodium | Pravastatin Sodium | 377 | 108 |
| Entresto | Sacubitril/Valsartan | 343 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 101 |
| Amiodarone Hcl | Amiodarone Hcl | 325 | 102 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 308 | 105 |
| Warfarin Sodium | Warfarin Sodium | 260 | 71 |
| Ranolazine Er | Ranolazine | 240 | 77 |
| Terazosin Hcl | Terazosin Hcl | 239 | 73 |
| Simvastatin | Simvastatin | 234 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 68 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 189 | 74 |
| Spironolactone | Spironolactone | 166 | 49 |
| Atenolol | Atenolol | 164 | 45 |
| Nitroglycerin | Nitroglycerin | 157 | 100 |
| Valsartan | Valsartan | 146 | 46 |
| Metolazone | Metolazone | 119 | 35 |
| Farxiga | Dapagliflozin Propanediol | 112 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 28 |
| Praluent Pen | Alirocumab | 97 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 92 | 29 |
| Ramipril | Ramipril | 91 | 26 |
| Alprazolam | Alprazolam | 80 | 16 |
| Irbesartan | Irbesartan | 79 | 25 |
| Nifedipine Er | Nifedipine | 76 | 20 |
| Multaq | Dronedarone Hcl | 71 | 16 |
| Bumetanide | Bumetanide | 66 | 21 |
| Benazepril Hcl | Benazepril Hcl | 65 | 18 |
| Prasugrel Hcl | Prasugrel Hcl | 65 | 12 |
| Minoxidil | Minoxidil | 59 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 17 |
| Allopurinol | Allopurinol | 48 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 14 |
| Enalapril Maleate | Enalapril Maleate | 45 | 13 |
| Gabapentin | Gabapentin | 44 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 43 | 17 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 42 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 42 | 16 |
| Clonidine Hcl | Clonidine Hcl | 40 | 24 |
| Klor-Con M20 | Potassium Chloride | 39 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | 15 |
| Lovastatin | Lovastatin | 38 | 11 |
| Sotalol | Sotalol Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Brilinta | Ticagrelor | 30 | 13 |
| Digoxin | Digoxin | 28 | 13 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Cartia Xt | Diltiazem Hcl | 26 | 17 |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 14 |
| Dilt-Xr | Diltiazem Hcl | 25 | 12 |
| Omeprazole | Omeprazole | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Sotalol Af | Sotalol Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Nitro-Dur | Nitroglycerin | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $923.81 · 67 records | Amgen Inc. | ARTIX MT, BodyGuardian, CAPVAXIVE, ELIQUIS, ESPRIT, FARXIGA, IN.PACT ADMIRAL, INSPIRE, JARDIANCE, LOKELMA, Labosys, LifeVest, MOUNJARO, REPATHA, TURBOHAWK, Topical Oxygen Chamber for extremities, ULTREON, VERQUVO, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error